Atrium Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	382.52	219.87	185.08	340.4	320.45
Short-Term Investments	1,314	1,282	410.27	270.33	85.1
Cash & Short-Term Investments	1,697	1,501	595.35	610.73	405.54
Cash Growth	13.01%	152.20%	-2.52%	50.59%	23.59%
Other Current Assets	101.6	40.79	15.96	12.22	5.6
Total Current Assets	1,798	1,542	611.31	622.94	411.14
Net Property, Plant & Equipment	74.61	18.29	16.65	15.01	15.59
Other Long-Term Assets	84.97	3.32	0.6	0.85	0.85
Total Assets	1,958	1,564	628.56	638.8	427.58
Accounts Payable	12.4	8.46	34.34	32.57	14.09
Accrued Expenses	157.47	64.73	14.34	11.19	8.94
Current Portion of Leases	3.94	3.84	3.64	3.11	1.77
Unearned Revenue	21.64	20.99	28.37	5.04	4.86
Total Current Liabilities	195.45	98.02	80.68	51.91	29.66
Long-Term Leases	45.31	2.96	6.21	7.58	9.96
Other Long-Term Liabilities	28.69	37.96	40.9	1.24	6.53
Total Long-Term Liabilities	74	40.92	47.11	8.82	16.49
Total Liabilities	269.45	138.94	127.79	60.73	46.15
Common Stock	0.02	0.01	0.01	0.01	0.01
Additional Paid-in Capital	3,264	2,315	1,071	939.31	566.16
Accumulated Other Comprehensive Income	2.56	2.9	0.13	-2.7	-0.19
Retained Earnings	-1,578	-893.07	-570.76	-358.54	-184.55
Shareholders' Equity	1,689	1,425	500.76	578.08	381.43
Total Liabilities & Equity	1,958	1,564	628.56	638.8	427.58
Total Debt	49.25	6.8	9.85	10.69	11.73
Net Cash (Debt)	1,648	1,495	585.5	600.04	393.81
Net Cash Growth	10.23%	155.29%	-2.42%	52.37%	20.36%
Net Cash Per Share	11.96	13.39	8.02	11.50	9.51
Book Value	1,689	1,425	500.76	578.08	381.43
Book Value Per Share	12.26	12.77	6.86	11.08	9.21
Tangible Book Value	1,689	1,425	500.76	578.08	381.43
Tangible Book Value Per Share	12.26	12.77	6.86	11.08	9.21